Tag: Sciences

Urovant Sciences announces its partnership with Holly Robinson Peet, actress and OAB patient, as part of the Time To Go™ campaign, an OAB awareness program. The Time to Go campaign aims to highlight the impact the disease can have on patients and present options for managing OAB symptoms so that people living with OAB feel more secure. comfortable asking for help finding a healthcare professional.

“We are thrilled to partner with Holly Robinson Peete to help raise awareness about overactive bladder and reduce the stigma surrounding the disease,” said James Robinson, CEO of Urovant Sciences. "We believe this collaboration will lead to greater awareness of symptoms and treatment options that may be helpful."

Overactive bladder causes sudden urges that are hard to control and can lead to leaking and frequent urination, usually eight or more times a day. Because millions of Americans experience bladder symptoms, the prevalence increases with age. Overactive bladder can negatively affect daily activities, such as B. changing travel plans, doing little or no exercise, and making daily activities difficult. Pete has first-hand experience with OAB, having been diagnosed last year, and has since dedicated his time and resources to managing the symptoms for himself and others.

Peete's overactive bladder diagnosis wasn't as obvious as he thought; she remembered accidentally having to go to the bathroom. At first, she thought the symptoms were a normal part of aging, especially since menopause was difficult for Pete at the time. She explained that offline address book symptoms are not necessarily part of aging and that we should discuss an appropriate plan for my symptoms,” she told ESSENCE.

Subsequently, her doctor recommended GEMTESA among her treatment options, a prescription drug to treat bladder problems in adults with episodic symptoms, urgency, and frequency of urination; Thinking about it, he wished he'd told the doctor sooner. "I had OAB symptoms for years before I talked to my doctor about treatment options and wish I had had some sooner," Pete said. "I realized that I used to go to the bathroom a lot and I suddenly had the urge to go, like now. With my overactive bladder symptoms, there was a lot of stress and anxiety before traveling for work or pleasure. I have noticed a positive effect on my offline address book symptoms with GEMTESA. By reducing my symptoms, I spend more time planning activities and less time plan the nearest toilets.

Pete isn't the only one who noticed his symptoms afterwards. According to a study published in the Journal of Urology, many people with symptoms of an overactive bladder are hesitant to see a doctor. This may be because they're too shy to talk about their symptoms or mistakenly believe it's part of normal aging.

Prior to taking GEMTESA, Pete had difficulty going out in public and was unable to train in the gym. He began to feel how his bladder was affecting his quality of life. "For the first time, I noticed that OAB was interrupting my work. Looking back, I have adjusted many aspects of my life. The first thing I asked upon entering the restaurant was: " Where's the toilet?" I even made special requests for the closets so I could go to the bathroom quickly and easily," says Pete.

Since GEMTESA is part of her wellness regimen, she has now improved her OAB symptoms and goes to the bathroom less often without worrying about being out of the house and the bathroom. He also thanks his group of trusted friends for his recovery. "My friends give me a lot of strength, so start with an honest and open conversation with them. They are the people I share my innermost thoughts and aspirations with, and maybe by sharing my story I can help one of them open up,” He says.

With this new campaign, Pete wants to encourage the black community to share their truth and get help. “In our community, we often feel uncomfortable talking about intimate matters, and when it comes to our bodies and our health, we shouldn't be. By being open about issues like an overactive bladder, we can help break down this often pervasive stigma. and get the attention we need,” he says.

Visit TimeToGo.com to learn more about OAB and GEMTESA®

Exact Sciences (EXAS) closed the last trading day at $67.92, down 0.67% from the previous trading session. The move was smaller than the S&P 500's 1.56% decline for the day. Elsewhere, the Dow lost 1.81% while the Tech-Nasdaq lost 4.66%.

The molecular diagnostics company's shares were up 33.84% month-on-month today. Meanwhile, the medical sector was up 0.86% and the S&P 500 was up 3.82%.

Investors are looking to Exact Science for strength as it heads into its next earnings report. In this report, analysts expect Exact Sciences to report earnings of -$0.92 per share. It will grow by 28.13% per year. Meanwhile, our latest agreed estimate was revenue of $527.13 million, up 11.25% from the year-ago quarter.

Investors should also pay attention to recent changes in analyst forecasts for the exact sciences. The recent correction reflects the recent short term trading trend. Thus, the positive revision of the forecast reflects analysts' optimism about the company's business and profitability.

Based on our research, we believe this rework is directly related to the team's inventory movement. We took advantage of this phenomenon and created Zacks Rank. Our system takes these changing assumptions into account and provides a clear and efficient scoring model.

Ranging from #1 (strong buy) to #5 (strong sell), the Zacks Rating system has an impressive track record, backed by external audits, with the #1 stock up +25% since 1988 Earning a CAGR. Last month, Zacks. The consensus EPS estimate is up 4.54%. Exact Science is currently ranked #2 Zack (Buy).

Drug. The biomedical and genetic industries are part of the medical sector. The industry currently has a Zacks 70 industry rating, placing it in the top 28% of 250+ industries.

Zacks Industry Ratings evaluates the strength of our industry group by measuring the average Zacks rating of each stock in the group. Our research shows that the top 50% of the industry outperforms the bottom by a factor of 2 to 1.

For more information on all of these metrics and more, visit Zacks.com.

To read this article on Zacks.com, click here.

Fed Day | See Bloomberg 14/12/2022

text size

Cancer testing company Exact Sciences did not expect to report the results until the September quarter. But test seller Cologuard said sales growth in the December quarter helped boost profits earlier than expected.

Sunday in Madison, Wisconsin. Revenue rose 28% to more than $550 million in the last quarter of 2022, according to preliminary data released by the company. Sales of colorectal cancer screening products, such as the Cologuard stool test, have increased by more than 40%.

MedCity Invest Precision medicine. The perfect move. Presentations of startups in the field of life sciences:

higher education

January 10, 2023

The Seton Hall Health Sciences Campus, home to the College of Medical and Health Sciences and the College of Nursing, will receive $1.14 million in federal funding announced by Congressman Bill Pascrell (NJ-9), said the Senators Robert Menendez and Cory Booker.

Congressman Pascrell said, "I have visited the IHS campus many times, and each time I have been incredibly impressed with the teaching and learning that takes place there. We are delighted to have been able to secure much-needed funding for this valuable project. The Skills Healthcare Staff Will Gain in The Future of Lab Upgrade New Jerseyans have been in the 9th District and throughout NJ for decades.

Anticipating the continued growth in demand for medical education, Seton Hall requested funding to:

• enhance the simulation lab experience;
• Construction of control rooms.
• simulation equipment
• and simulation at the point of care.

The project will provide new equipment and enhancements to the Simulation Center on the IHS campus to ensure that nurses, occupational therapists, physician assistants, physical therapists, speech therapists, and sports trainers are clinically prepared to interact with real patients.

Catherine Sanuk, Coordinator of the Clinical Skills Laboratory, School of Nursing; With Jennifer McCarthy, Director of Clinical Simulations in the College of Health Sciences and Medicine; Preparation of financing proposal.

“The upgrades and equipment will enable the College of Nursing and the College of Health Sciences and Medicine to prepare future healthcare professionals to work in a patient-centered, integrated healthcare system, addressing healthcare shortages. and demand,” Sanuk and McCarthy noted.

Adds Joseph E. Nair, Ph.D., president of Seton Hall, "This achievement is the result of months of dedicated work by the faculty and staff of the College of Nursing and the College of Health and Medical Sciences, and our relationship with Seton Hall's management team and advocates in the nation's capital, such as Congressman Pasquerel and Senator Booker and Menendez, are grateful to each of them for their dedication to Seton Hall and the health of NJ.

For more business news, visit NJB News Now .

Related Posts:

Sixth Edition of the CMC Series with Seton Hall University: Your Guide to Running a Virtual Case Competition

© Courtesy of Benzinga

New York-based Perception Neuroscience, the clinical-stage psychedelic biotechnology company Atai Life Sciences (NASDAQ: ATAI ), announced the results of its PCN-101 study of a specific R-ketamine in patients with treatment-resistant depression (TRD).

Although the combination showed signs of efficacy at all time points, the study did not reach the primary endpoint of a statistically significant change from baseline in participants' MADRS (Montgomery-Asberg Depression Rating Scale) at 24 hours compared to placebo, the company said. The MRS is a widely used clinically assessed measure of depression severity.

A two-week trial study evaluated the safety, tolerability, and efficacy of a single intravenous injection of PCN-101 in 102 patients with TRD.

Other primary endpoints were the proportion of patients defined as responders, i.e. the proportion of patients with a 50% improvement from baseline on the MADRS and the proportion of patients with an overall MADRS score of less than 10.

Trending: Elon Musk says if Putin dies or is ousted, his successor in the UK will not be 'friendly' to the world

Should read : "Não nos pode jahil". Aki Estamos Nos' – Brock Pierce sobre or Blockchain Hub Davos 2023

For these measures, the study did not reach statistical significance, although response and remission rates were higher in the 60 mg group.

PCN-101 was generally well tolerated, with remission and withdrawal rates comparable to placebo.

Based on the overall results, Atai said it will look closely at the study data and work with understanding on next steps, "not limited to exploring strategic partnership options."

After this news, the share price of the company fell. Shares fell 30% to close at $1.86 per share.

Image: Benzinga via RODNAE Productions on Pixel and Doc James on Wikimedia Commons.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Spiritual masters make simple promises and deliver nothing

Gilead Sciences has pledged billions of dollars to Galapagos in an autoimmune disease partnership that is far from expected. But the drugmaker is not giving up on this therapeutic area and is now forming a new alliance with a new partner whose technology could offer treatments for rheumatoid arthritis and lupus.

The partner is EVOQ Therapeutics, a startup whose technology takes a novel approach to the antigen-specific immune response. Specific financial terms of the deal announced Tuesday were not disclosed, but the companies said EVOQ could receive up to $685.5 million in upfront payments, exercise options and milestone payments.

Autoimmune diseases develop when the balance of the immune system is shifted towards hyperactivation of immune cells. EVOQ's approach to treating such diseases targets dendritic cells, antigen-presenting cells that prime immune cells for immune tolerance or immune activation responses. The company says its technology can stimulate dendritic cells to trigger an anti-inflammatory response that restores immune tolerance.

The EVOQ technology, known as NanoDisc, is designed to deliver disease-specific antigens to lymph nodes, which are rich reservoirs of dendritic cells. Under the terms of the agreement with Gilead, both companies will collaborate on preclinical research. The agreement allows Gilead to license the NanoDisc technology exclusively for rheumatoid arthritis and lupus. If the Foster City, California-based drugmaker exercises those options, it will be responsible for the clinical development of drug candidates. If the drugs receive regulatory approval, Gilead will also market them. EVOQ will then receive royalties from sales of Gilead's commercial products.

"Despite great advances in the last two decades, there remains a significant unmet need for people with inflammatory and autoimmune diseases," said Flavius ​​Martin, Gilead's executive vice president of research. "We are excited to partner with EVOQ to further expand our autoimmune line to meet the needs of people living with the condition."

Gilead expressed similar sentiments in 2019 when it reached a $5 billion deal with Galapagos to collaborate on six drugs in clinical phase and another 20 in preclinical development. The agreement expanded on a previous alliance for filgotinib, which was rejected by the FDA but received regulatory approval in Japan and Europe for the treatment of rheumatoid arthritis. Although Gilead collects royalties on sales of its partner's product, most of the drug is now owned by Galapagos. Other affiliate programs have also failed. In 2021, Gilead and Galapagos halted the development of giritaxate in idiopathic pulmonary fibrosis after an independent data monitoring committee evaluated the clinical data and concluded that the drug's benefits did not outweigh its risks.

Gilead is EVOQ's second pharmaceutical partner. Two years ago, the startup announced a secret licensing and collaboration agreement with Amgen to cover the development of new drugs for autoimmune diseases. The deal puts EVOQ in line for up to $240 million in initial and milestone payments.

Photo: David Paul Morris/Bloomberg via Getty Images

The clinical trial landscape in primary sclerosing cholangitis: current and new opportunities for patients

©PT.I

Nagpur, Jan 3 (PTI) Prime Minister Narendra Modi on Tuesday laid out his vision for science for the next 25 years, urging researchers to focus on making the nation self-sufficient and transforming their knowledge to make a difference in everyone's lives.

Inaugurating the 108th Indian Science Congress here, Modi emphasized strengthening scientific processes, focusing on new areas such as quantum technology, data science, developing new vaccines, strengthening efforts to monitor new diseases, and encouraging young people to do research.

©PT.I

“Science endeavors can become great accomplishments only when they leave the laboratory and reach the world, and their impact extends from the global to the grassroots level, from the journal to the ground (Earth, everyday life) and change is visible. From research. For real life," the prime minister said in a virtual address at the event.

©PT.I

The five-day Indian Science Congress kicked off at Rashtrasant Tukdoji Maharaj University in Nagpur in the presence of Maharashtra Governor Bhagat Singh Kashiari, Union Ministers Nitin Gadkari and Jitendra Singh, Chief Minister Eknath Shinde and Deputy Chief Minister Devendra Fadnavis.

The Prime Minister also took the important step of creating an institutional framework and teacher mentor system (guru shishi) that could build on successful talent hunts and hackathons to attract young people to science.

He highlighted opportunities for private companies and startups to connect with research labs and academic institutions. He urged researchers to focus on quantum computing and become world leaders in the future.

"India is moving fast towards quantum computing, chemistry, communications, sensors, cryptography and new materials," said Modi, urging young researchers and scientists to gain experience and become leaders in the quantum field.

The Prime Minister urged researchers to prioritize topics such as artificial intelligence, augmented and virtual reality and propose innovations in semiconductors.

"India is taking several initiatives in the semiconductor field. New innovations will be needed in the semiconductor field. Shouldn't we be thinking in this direction to shape the future of the country?" Dr Modi.

Addressing India's growing energy needs, he urged the scientific community to develop innovations that could benefit the country in this field.

Since India is home to 17-18 percent of the world's population, the development of so many people will also bring about global prosperity, he said.

India is leveraging science for progress and its impact is visible, he said, noting that India rose from 81st to 40th position in the 2015 Global Innovation Index out of 130 countries.

"Currently, we are living in a time when humanity is facing the threat of new diseases. We need to timely detect diseases through comprehensive disease control and take measures to fight them. Different ministries need to work together to achieve this." she says

Modi also stressed the importance of strengthening research and development to develop new vaccines.

Worst company in the world!! Blackstone and Blackrock

© The Motley Fool This new drug could be a catalyst for Gilead Sciences' growth

Gilead Sciences (NASDAQ:GILD) is one of the year's biggest stocks, up 17%, while the S&P 500 is down 21% over the same period. And the company may have given investors reason to remain optimistic about the stock. Health officials have given the go-ahead for another HIV treatment that promises to improve lives and generate billions in corporate revenue. Is it time to stockpile Gilead?

FDA approved lenacapavir

On December 22, Gilead Sciences issued a press release announcing that the Food and Drug Administration (FDA) had approved an HIV treatment, lenacapavir, to be marketed as Sunlenca. This treatment is approved for people with multidrug-resistant HIV. The six-monthly injection will give many HIV patients a longer option than the daily pill they are currently on. Importantly, it is not approved for everyone with HIV, only for those "who cannot be successfully treated with other available therapies because of resistance, intolerance or safety concerns."

For investors, this is as important a win as success for Gilead. Analysts estimate that lenacapavir could generate $1.5 billion in revenue at its peak. This will represent approximately 5.5% of the $27 trillion in product sales reported by Gilead last year.

In terms of value for money, it may not be a game changer, but it's still a significant accomplishment for Gilead. CEO Daniel O'Day said, “Gilead scientists have developed the unique and powerful antiretroviral drug Sunlenca with flexible dosing options. Our goal is to provide multiple long-term care options.

Gilead is actually positioning itself to be in the best position to capitalize on the growing need for HIV care. Fortune Business Insights estimates that the global HIV drug market will be valued at over $45 trillion by 2028, and a compound annual growth rate of 5.9% until then.

Gilead could use a growth catalyst

One of Gilead's recent challenges has been finding ways to ensure sustainable growth, and Sunlenca can help. Over the past three quarters, Gilead's revenue excluding the COVID-19 drug Vecluri was $16.7 billion, up just 7% year-over-year. And the growth rate of its largest segment, HIV, is even lower, at just 5%. Therefore, Sunlenca's agreement gives investors an opportunity to bounce back and be able to generate even stronger growth in the future.

The stock is currently trading at multiples of 13 (less than the health average of 17), indicating that investors are a little wary of the company and unsure of its upside potential. Gilead stock has yet to receive FDA approval, but the stock likely has lost money in recent months, thanks in part to strong earnings reports and generally favorable market growth prospects for the stock. While this is a big win for the company, the backing may not be enough (financially) to push the stock higher than before.

Is Gilead Sciences a Share Buyback?

Gilead Sciences has a strong HIV business that recently got another opportunity with support from Sunlenca. Despite increasing value, Gilead shares are not overvalued and are still a bargain. And with a dividend yield of 3.5%, there's even an added incentive to buy and own medical stocks because they are an investment that can be a good source of regular cash flow for your portfolio.

Sponsors:

10 stocks we like better than Gilead Sciences

When our award-winning team of analysts has valuable advice, it's worth listening. After all, the Motley Stock Advisor newsletter, which has been around for over a decade, has doubled the market*.

Investors just named ten stocks they believe are the best buys right now… and Gilead Sciences isn't one of them! That's right: they think those 10 stocks are a better buy.

View 10 promotions

* Exchange Advisor returns on December 1, 2022.

David Jagielski was not interested in this action. Motley Fool has and recommends positions at Gilead Sciences. Motley Fool has a disclosure policy.

7 BEST BIOTECH STOCKS TO BUY IN 2022!

Shares of Guardian Health Sciences Inc. (NASDAQ: GHSI ) rose on Friday 12/30/22 as the stock price rose 0.76% from the previous day's close as strong buying pushed the stock up $0.15.

Actively tracking price action in recent trades, the stock closed the session at $0.14, reaching a range of $0.142 to $0.151. The beta value (monthly after 5 years) was 0.85. Referring to the stock's 52-week performance, the high was $0.74 and the low was $0.13. Overall, the GHSI changed by -15.88% over the past month.

As the market capitalization of Guardian Health Sciences Inc. currently stands at around $9.21M, investors are looking forward to the results for this quarter which is expected from March 30, 2023 to April 3, 2023. Therefore, investors may wish for the stock to increase in value. before the company releases its earnings report. Analysts expect the company's earnings per share (EPS) to be $-0.03, which is expected to decrease to $-0.05 in FY-0.15 and then to around $-0.13 by FY2023. year.

Analysts estimated the company’s revenue for the quarter at $2.95 million, with a low estimate of $2.7 million and a high estimate of $3.2 million.

Reviews can be a useful indicator for understanding short-term price movements; therefore, there have been no bullish or bearish changes over the past seven days. We can see the technical chart of the GHSI, which shows that the short-term indicators are showing that the stock is selling at an average of 50%. However, medium-term indicators place the stock in the Hold category, while long-term indicators put the stock at 100% on average.

1 analyst(s) rated their futures rating on the stock on a scale of 1.00 to 5.00, indicating a strong buy or sell recommendation. The stock has 0 analyst hold ratings, 1 buy rating and 0 GHSI Stock Overweight ratings. Meanwhile, 0 analysts think the stock is underweight and 0 think it is a sell. Therefore, investors who want to increase their stake in the company's shares will have the opportunity to do so, as the average rating of the stock is a buy.

Technical analysis of the stock shows that PEG ratio is close to zero and GHSI price is currently trading close to -9.88% and -10.33% from its 20 and 50 day simple moving averages respectively. The Relative Strength Index (RSI, 14) is currently at 40.71, and the 7-day volatility report shows 6.71%, or 9.40% on the 30-day chart. Also, Guardian Health Sciences Inc.'s beta value. (GHSI) is 0.88 and its Average True Range (ATR) is 0.01. The company's stock price is expected to average $0.60 over the next 52 weeks, with a low of $0.60 and a high of $0.60. Based on these price targets, the low is -300.0% of the current price, while the price is expected to move -300.0% to the high of the year. Additionally, investors should welcome the analyst average price of $0.60 as it represents a -300.0% downside from current levels.

Historical trading data from Guardian Health Sciences Inc. (NASDAQ:GHSI) shows an average trading volume of 0.57 million shares over the past 10 days and 1.09 million shares over the past 3 months.

About 1.34% of Guardian Health Sciences Inc. owned by insiders, while institutional investors own 7.70% of the company's shares. The short interest data also shows that there were 5.43 million shares shorted as of December 14, 2022, corresponding to a short put ratio of 6.86. According to the data, a low stake in Guardian Health Sciences Inc. (GHSI) was 8.82% of shares outstanding as of December 14, 2022; the number of short shares recorded on November 14, 2022 reached 5.57 million. The stock is down 77.58% year-to-date, indicating further upside potential. This could boost investors' confidence that they are bullish on GHSI stock next quarter.

GUARDION HEALTH SCIENCES INC AWARDS FOR YOU | GHSI BUCKS ANALYSIS | GHSI BUCKS FORECAST